Remus Pharmaceuticals share news, announcements and annual reports
NSE: REMUSPharmaceuticals & Biotechnology
Share price at the NSE close on 30 Oct 2026. Previous close ₹873.80.
30 Oct: open ₹855.00, high ₹855.00, low ₹830.10
- Next results date: the board meets on 3 Nov 2026 to consider: financial results, dividend and other business matters. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. Market capitalisation: how it is worked out
- ₹994 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 26.87
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.83
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.12%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 12.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 13.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.06
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 5,70066.7% delivered
Remus Pharmaceuticals has 144 announcements on record, routine notices left out; 3 in the 30 days to 1 Nov 2026, the latest on 28 Oct 2026.
Next board meeting and results date
As the company gave notice to the exchange.Remus Pharmaceuticals half-yearly results
The board meets on 3 Nov 2026 to consider financial results, dividend and other business matters
Notice filed 28 Oct 2026
Remus Pharmaceuticals annual reports, presentations and earnings calls
The company's own documents, latest first.Remus Pharmaceuticals financials, year by year
Annual reports4
- Annual report, year to Mar 20267 Sep 2026
- Annual report, year to Mar 20252 Sep 2025
- Annual report, year to Mar 202429 Aug 2024
- Annual report, year to Mar 202331 Aug 2023, a zip file
Investor presentations5
- Investor Presentation21 May 2026
- Investor Presentation10 Nov 2025
- Investor Presentation20 Aug 2025
- Investor Presentation19 May 2025
- Investor Presentation15 Nov 2024
Earnings calls8
- Transcript28 May 2026
- Audio recordings of Earnings Conference Call for the half year and financial year ended March 31, 202621 May 2026
- Transcript15 Nov 2025
- Link of Recording11 Nov 2025
- Transcript of the Earnings Conference Call H2 and FY2024-2523 May 2025
3 earlier call documents
Remus Pharmaceuticals share news and announcements
Newest first. Page 1 of 3.
Oct 2026
28 Oct · Analysts
7 Oct · Meeting
Sep 2026
29 Sep · Meeting
7 Sep · Corporate action
5 Sep · Meeting
Jun 2026
23 Jun · Board meeting
22 Jun · Management
22 Jun · Management
May 2026
20 May · Business
20 May · Results
20 May · Results
Apr 2026
Mar 2026
17 Mar · Analysts
Dec 2025
16 Dec · Meeting
2 Dec · Analysts
2 Dec · General Updates
Nov 2025
12 Nov · Meeting
10 Nov · Business
10 Nov · Results
6 Nov · Analysts
1 Nov · Corporate action
Oct 2025
Sep 2025
2 Sep · Corporate action
Aug 2025
29 Aug · Board meeting
13 Aug · Analysts
Jul 2025
24 Jul · General Updates
7 Jul · Board meeting
Jun 2025
24 Jun · Corporate action
23 Jun · Meeting
23 Jun · Meeting
20 Jun · Board meeting
How the price met the news
The first session after each announcement, beside the market.
That dayThe first session's move. The first session's close after the announcement against the close before it, as a per cent change, on prices adjusted for splits and bonuses.Against the Nifty 500Against the Nifty 500. The share's move less the Nifty 500's move the same session, in percentage points (pts).Market median on that newsThe market's median move on that news. The middle first-session move of every listed company that filed the same kind of announcement, half moving more and half less.Five sessionsFive sessions' move. The close five sessions after the announcement against the close before it, as a per cent change.Five sessions against the Nifty 500Five sessions against the Nifty 500. The share's five-session move less the Nifty 500's move over the same five sessions, in percentage points (pts).Volume, times usualVolume, times usual. The session's shares traded divided by the average of the twenty sessions before it.
- 23 Jun 2026Board or managers changedup 1.77%+2.9 pts vs Nifty 500market median 0.0% · five sessions −0.5% (+0.6 pts vs Nifty 500) · volume 0.5× usual · The announcement
- 20 May 2026Resultsdown 2.99%−3.2 pts vs Nifty 500market median −0.7% · five sessions −16.1% (−17.8 pts vs Nifty 500) · volume 3.4× usual · The announcement
- 10 Nov 2025Resultsup 1.07%+0.7 pts vs Nifty 500market median −0.7% · five sessions −8.0% (−9.4 pts vs Nifty 500) · volume 0.6× usual · The announcement
- 19 May 2025Board or managers changeddown 4.02%−4.0 pts vs Nifty 500market median 0.0% · five sessions −9.2% (−8.8 pts vs Nifty 500) · volume 1.4× usual · The announcement
- 11 Nov 2024Dividenddown 2.72%−2.5 pts vs Nifty 500market median 0.0% · five sessions −9.6% (−6.3 pts vs Nifty 500) · volume 2.2× usual · The announcement
- 24 Apr 2024Dividendup 19.61%+19.2 pts vs Nifty 500market median 0.0% · five sessions +6.6% (+4.9 pts vs Nifty 500) · volume 12.1× usual · The announcement
- 8 Feb 2024Board or managers changedup 5.35%+6.0 pts vs Nifty 500market median 0.0% · five sessions −1.8% (−0.8 pts vs Nifty 500) · volume 1.6× usual · The announcement
- 19 Oct 2023Dividendup 0.80%+1.0 pts vs Nifty 500market median 0.0% · five sessions −2.9% (+1.7 pts vs Nifty 500) · volume 1.2× usual · The announcement
Remus Pharmaceuticals results filing dates and deadlines
Listed companies must file half-yearly results within 45 days, and the year's within 60.
Days to fileDays to file. The days from the period's end to the day the results reached the exchange.DeadlineDeadline, days. The days the rules allow from the period's end: 45 for a quarter or half year, and 60 for the year and the March quarter filed with it. A company that listed after the period ended has until 21 days after its listing where that is later.